Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Mitchell

Showing results (111-120 of 113) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 113 results.
The Journal of Clinical Investigation|November 19, 2010
Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humansErik Schoenmakers, Maura Agostini, Catherine Mitchell, et al.
Nature Communications|May 20, 2025
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primaryRichard J Rebello, Atara Posner, Ruining Dong, et al.
European Urology|July 28, 2018
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed TherapyMitchell G Lawrence, Daisuke Obinata, Shahneen Sandhu, et al.
Pageof 12

Showing results (111-120 of 113) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 113 results.
The Journal of Clinical Investigation|November 19, 2010
Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humansErik Schoenmakers, Maura Agostini, Catherine Mitchell, et al.
Nature Communications|May 20, 2025
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primaryRichard J Rebello, Atara Posner, Ruining Dong, et al.
European Urology|July 28, 2018
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed TherapyMitchell G Lawrence, Daisuke Obinata, Shahneen Sandhu, et al.
Pageof 12